IL-17A, His, Human Protein
- Known as:
- Interleukin-17A, histidine, Human Protein
- Catalog number:
- z03228-10
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- Genscript
- Gene target:
- IL-17A His Human Protein
Related genes to: IL-17A, His, Human Protein
- Gene:
- IL17A NIH gene
- Name:
- interleukin 17A
- Previous symbol:
- CTLA8, IL17
- Synonyms:
- IL-17A, IL-17
- Chromosome:
- 6p12.2
- Locus Type:
- gene with protein product
- Date approved:
- 1993-10-25
- Date modifiied:
- 2019-04-23
Related products to: IL-17A, His, Human Protein
Related articles to: IL-17A, His, Human Protein
- The purpose of this study was to characterize the intraocular cytokine context of growth differentiation factor 15 (GDF15), a stress-response cytokine implicated in tissue injury and immune regulation, in eyes with idiopathic epiretinal membrane (iERM) by evaluating paired aqueous humor (AH) and vitreous humor (VH) samples and their compartment-specific associations with other soluble cytokines. - Source: PubMed
Mieno HirokiHashida MasatsuguYoshii KengoToda MunetoyoHorikiri TomokoUrabe KimiakiMori KazuhikoUeno MorioSotozono Chie - Meningoencephalitis of unknown origin (MUO) encompasses a heterogeneous group of non-infectious, presumed autoimmune, central nervous system diseases in dogs and remains a major therapeutic challenge in veterinary neurology. Mounting evidence from both experimental and clinical studies has highlighted the pivotal role of T helper 17 (Th17) cells and their proinflammatory cytokines, especially interleukin-17A (IL-17A), in mediating neuroinflammation similar to that seen in experimental autoimmune encephalomyelitis (EAE) and multiple sclerosis (MS) models. REV-ERBs are nuclear receptors that act as transcriptional repressors and regulate immune responses, circadian rhythm, and metabolism. Synthetic REV-ERB agonists, such as SR9009, SR9011, and SR12418, have demonstrated selective suppression of Th17 differentiation and function, reduction of disease severity, and improved safety profiles in preclinical autoimmune models. In addition to Th17 differentiation, REV-ERB's role in other components of the immunomodulating system is ever-growing. Preclinical and translational data support the further exploration of REV-ERB agonists as a potential addition to the targeted immunomodulatory therapies for canine MUO. By continuing to investigate REV-ERB compounds as a component of MUO therapy, researchers can assess their potential for improved efficacy and reduce the side effects associated with traditional immunosuppressive regimens. This review integrates mechanistic insights from immunology, circadian biology, and experimental models, and outlines future directions for clinical translation, highlighting the relevance of REV-ERB agonists in advancing veterinary neuroimmunology and in informing comparative approaches to human neuroautoimmune disease. - Source: PubMed
Publication date: 2026/07/21
Bailey AshtonGibson RyanGriffett Kristine - Psoriasis is an immune-mediated inflammatory skin disorder associated with systemic complications, including an elevated risk of chronic kidney disease (CKD) and progression to end-stage renal disease (ESRD). Managing psoriasis in patients undergoing peritoneal dialysis (PD) remains challenging, primarily due to contraindications to conventional systemic therapies and the limited evidence regarding biologic agents in this population. We report a case of severe psoriasis successfully treated with secukinumab in a 61-year-old man on PD. The patient was diagnosed with plaque psoriasis six years after dialysis initiation. Although initial symptoms improved with intensified dialysis and topical corticosteroids, the disease subsequently was exacerbated, presenting with extensive lesions and severe generalized pruritus that significantly impaired sleep quality. Secukinumab was initiated at 300 mg subcutaneously weekly for four weeks, followed by a maintenance dose of 300 mg every four weeks. At 12 months, the patient achieved complete clearance of psoriatic lesions with no adverse events or PD-related complications. This case highlights the paradoxical role of dialysis in psoriasis, which may either induce new-onset disease or ameliorate pre-existing lesions. Furthermore, it supports the efficacy and safety of secukinumab for severe psoriasis in PD patients. While IL-17A is implicated in dialysis-induced peritoneal damage, whether IL-17A inhibitors confer protective benefits on peritoneal membrane integrity in this population remains unknown and warrants dedicated investigation. Further studies are urgently needed to establish evidence-based guidelines for secukinumab use in PD patients. - Source: PubMed
Publication date: 2026/07/08
Fang JunyanLi RuolinXie YingxinLiu Yingli - Airway remodeling (AR) is a key pathological feature of chronic lung diseases and is closely associated with disease progression. IL-17A has been implicated in airway inflammation and fibrosis, but its role in AR and the underlying mechanisms remain incompletely understood. This study investigated whether IL-17A regulates bronchial fibroblast autophagy and airway remodeling through the PI3K/AKT/mTOR pathway. - Source: PubMed
Publication date: 2026/07/08
Liu YutingZhou JianAn XuanGu YanhuiZhang LanyingMa YueTang QingpiaoYu ShengyiOuyang Yao - Inflammatory bowel disease (IBD) is a relapsing inflammatory disorder of the gastrointestinal tract with increasing global incidence. Current therapies are often limited by side effects, loss of efficacy, and high cost, underscoring the need for safer and more effective alternatives, particularly multi-target agents derived from natural products. - Source: PubMed
Publication date: 2026/07/23
Bao YinAo QiangWang MengMao XiaolingZhu JunZhang MingyueChen YangZhu HongGao Jun